.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Mallinckrodt
Queensland Health
Deloitte
Citi
Healthtrust
Daiichi Sankyo
Baxter
Colorcon
QuintilesIMS

Generated: December 18, 2017

DrugPatentWatch Database Preview

LOCOID Drug Profile

« Back to Dashboard

When do Locoid patents expire, and what generic alternatives are available?

Locoid is a drug marketed by Precision Dermat and Yamanouchi and is included in eight NDAs. There are two patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in LOCOID is hydrocortisone butyrate. There are sixty drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the hydrocortisone butyrate profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Precision DermatLOCOIDhydrocortisone butyrateCREAM;TOPICAL018514-001Mar 31, 1982AB1RXYesYes► Subscribe► Subscribe► Subscribe
Precision DermatLOCOIDhydrocortisone butyrateSOLUTION;TOPICAL019116-001Feb 25, 1987ATRXYesYes► Subscribe► Subscribe► Subscribe
Precision DermatLOCOIDhydrocortisone butyrateLOTION;TOPICAL022076-001May 18, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
YamanouchiLOCOIDhydrocortisone butyrateSOLUTION;TOPICAL019819-001Sep 15, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
YamanouchiLOCOIDhydrocortisone butyrateCREAM;TOPICAL018795-001Jan 7, 1983DISCNNoNo► Subscribe► Subscribe► Subscribe
Precision DermatLOCOIDhydrocortisone butyrateLOTION;TOPICAL022076-001May 18, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
YamanouchiLOCOIDhydrocortisone butyrateOINTMENT;TOPICAL019106-001Jul 3, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Precision DermatLOCOIDhydrocortisone butyrateOINTMENT;TOPICAL018652-001Oct 29, 1982ABRXYesYes► Subscribe► Subscribe► Subscribe
Precision DermatLOCOID LIPOCREAMhydrocortisone butyrateCREAM;TOPICAL020769-001Sep 8, 1997AB2RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for LOCOID

Drugname Dosage Strength RLD Submissiondate
hydrocortisone butyrateLotion0.1%Locoid8/31/2016
hydrocortisone butyrateCream0.1%Locoid Lipocream6/28/2010

Premature patent expiration for: LOCOID

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
► Subscribe LOCOID ► Subscribe

Non-Orange Book Patents for Tradename: LOCOID

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,389,502Stabilized steroid composition and method for its preparation► Subscribe
8,546,364Stabilized steroid composition and method for its preparation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Cantor Fitzgerald
Mallinckrodt
Merck
Medtronic
UBS
Accenture
Citi
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot